NeoGenomics (NASDAQ:NEO) Shares Down 7.4% – Here’s What Happened

Shares of NeoGenomics, Inc. (NASDAQ:NEO) fell 7.4% on Monday . The company traded as low as $12.72 and last traded at $12.1880. 585,490 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 1,450,509 shares. The stock had previously closed at $13.16.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on NEO shares. Needham & Company LLC reiterated a “buy” rating and issued a $14.00 target price on shares of NeoGenomics in a research report on Monday. Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a report on Wednesday, January 7th. Leerink Partners set a $14.00 price objective on shares of NeoGenomics in a research note on Tuesday, October 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.00.

NeoGenomics Stock Performance

The company has a current ratio of 3.91, a quick ratio of 3.62 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $11.57 and its two-hundred day moving average price is $9.07. The stock has a market capitalization of $1.62 billion, a PE ratio of -14.19 and a beta of 1.58.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, beating the consensus estimate of $0.02 by $0.01. The company had revenue of $187.80 million for the quarter, compared to analyst estimates of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The firm’s revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business earned $0.05 earnings per share. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. As a group, equities research analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insiders Place Their Bets

In other NeoGenomics news, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $12.00, for a total transaction of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares in the company, valued at approximately $372,996. This represents a 40.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On NeoGenomics

Institutional investors have recently added to or reduced their stakes in the stock. Aster Capital Management DIFC Ltd increased its stake in shares of NeoGenomics by 42.5% during the third quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock worth $26,000 after purchasing an additional 997 shares in the last quarter. Headlands Technologies LLC purchased a new stake in NeoGenomics during the 2nd quarter worth approximately $32,000. GAMMA Investing LLC increased its stake in NeoGenomics by 68.2% during the 4th quarter. GAMMA Investing LLC now owns 3,602 shares of the medical research company’s stock worth $42,000 after buying an additional 1,460 shares in the last quarter. Capstone Financial Advisors Inc. acquired a new position in shares of NeoGenomics during the second quarter valued at approximately $73,000. Finally, Captrust Financial Advisors purchased a new position in shares of NeoGenomics in the second quarter valued at approximately $75,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.